|
Christine,
Could you find out if a low reading the test could potentially help to discover that, while Herceptin is making HER-2 tumours regress, other HER-2 negative lesions are progressing (or not regressing) by comparing with other non selective existing markers?
If so, this would allow the onc to add other treatments to Herceptin at an oppotune time.
|